Prescription drugs; price transparency. (HB1436)

Introduced By

Del. Chris Hurst (D-Blacksburg) with support from co-patrons Del. Patrick Hope (D-Arlington), Del. Mark Levine (D-Alexandria), Del. Marcus Simon (D-Falls Church), Sen. Jennifer Boysko (D-Herndon), and Sen. John Edwards (D-Roanoke)

Progress

Introduced
Passed Committee
Passed House
Passed Senate
Signed by Governor
Became Law

Description

Prescription drug price transparency. Requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the State Health Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug; any changes in the average wholesale price and average wholesale acquisition cost of the prescription drug; the amount of profits derived from sale of the prescription drug; and the total amount of financial assistance provided to consumers of the prescription drug. The bill adds this reported data to the list of reports that the Commissioner causes to be published on a website maintained by a nonprofit entity with which the Commissioner has entered into a contract for such purpose and requires the Commissioner to annually report on such information, in aggregate form, to the Chairmen of the House Committees on Appropriations and on Health, Welfare and Institutions and the Senate Committees on Finance and on Education and Health. The measure has a delayed effective date of January 1, 2019. Read the Bill »

Outcome

Bill Has Failed

History

DateAction
01/16/2018Committee
01/16/2018Presented and ordered printed 18101421D
01/16/2018Referred to Committee on Health, Welfare and Institutions
01/23/2018Referred from Health, Welfare and Institutions
01/23/2018Referred to Committee on Commerce and Labor
01/31/2018Impact statement from VDH (HB1436)
02/01/2018Passed by indefinitely in Commerce and Labor (11-Y 6-N) (see vote tally)